redcordial - it's both actually but the necessity to continue the use of interferon-based treatment regimens in over 80% of patients is more of a striking concern to me than combination with ribavirin. (ref: Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C (FDA)).
Benitec is targeting genotype 1 in the upcoming trial, by the way.